Cialis Standard Titration Schedule

Why Tadalafil Titration Matters

Getting the dose right with tadalafil is not about prescribing the highest available strength. It is about finding the minimum effective dose that produces reliable results with the fewest side effects. The FDA-approved prescribing information specifies two separate dosing paradigms because tadalafil's 17.5-hour half-life supports both scheduled daily use and episodic on-demand use [1].

The Clinical Rationale for Starting Low

Tadalafil inhibits phosphodiesterase type 5 (PDE5) in vascular smooth muscle, increasing cyclic GMP and promoting penile blood flow during sexual stimulation. Starting at the lower end of the dose range allows the prescriber to gauge vascular responsiveness while minimizing the risk of headache, flushing, dyspepsia, and nasal congestion. In Brock et al.'s 12-week randomized controlled trial (N=1,112), tadalafil 10 mg and 20 mg both produced statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score versus placebo, but adverse events were dose-dependent [2]. Back pain and myalgia, for instance, appeared more often at 20 mg than at 10 mg.

Two Paths, One Drug

Daily dosing builds a steady-state plasma concentration within approximately 5 days, providing continuous PDE5 inhibition. On-demand dosing delivers a single pharmacokinetic peak. Choosing between them depends on sexual activity frequency, patient preference, and whether BPH symptoms are also a treatment target. The American Urological Association (AUA) notes that daily low-dose tadalafil is the only PDE5 inhibitor approved for concurrent ED and BPH management [3].

Daily Dosing Titration: 2.5 mg to 5 mg

The daily regimen is designed for men who anticipate sexual activity at least twice per week or who have coexisting lower urinary tract symptoms (LUTS) from BPH. The schedule below reflects the FDA label and supporting trial data.

Step 1: Initiate at 2.5 mg

Prescribe tadalafil 2.5 mg once daily, taken at the same time each day regardless of sexual activity. No food timing restriction applies. Steady-state concentrations are reached by day 5 due to the long half-life [1]. Advise the patient that full efficacy may not be apparent for several days.

Step 2: Evaluate at 4 to 8 Weeks

After a minimum of 4 weeks (the Endocrine Society recommends at least 4 adequate attempts at intercourse before concluding non-response [4]), reassess using a validated instrument such as the IIEF-5 (Sexual Health Inventory for Men, or SHIM). If the SHIM score remains below 22 and the patient reports no bothersome side effects, dose escalation is appropriate.

Step 3: Escalate to 5 mg Daily

Increase to 5 mg once daily. This is the ceiling for the daily regimen. The prescribing label does not support doses above 5 mg for daily use [1]. If 5 mg daily is ineffective after another 4 to 8 weeks, the clinician should reconsider the diagnosis, assess for contributing comorbidities (diabetes, hypogonadism, psychogenic factors), or switch to on-demand dosing at 10 to 20 mg.

When to Stay at 2.5 mg

Patients on moderate CYP3A4 inhibitors (erythromycin, fluconazole) should generally remain at 2.5 mg daily. For potent CYP3A4 inhibitors such as ketoconazole or ritonavir, the FDA recommends a maximum of 2.5 mg daily [1]. Alpha-blocker co-administration also warrants starting at the lower dose with blood-pressure monitoring.

On-Demand Dosing Titration: 10 mg Start, 5 to 20 mg Range

On-demand tadalafil suits men with less frequent sexual activity or those who prefer not to take a daily medication. The half-life makes timing more flexible than with shorter-acting PDE5 inhibitors.

Step 1: Start at 10 mg

The FDA label recommends 10 mg taken prior to anticipated sexual activity, at least 30 minutes before intercourse [1]. Unlike sildenafil, tadalafil absorption is not meaningfully affected by food, including high-fat meals. The drug reaches peak plasma concentration (Cmax) at a median of 2 hours but can produce clinical effect as early as 30 minutes in some men, per the integrated analysis by Porst et al. (N=1,112 across pooled trials) [5].

Step 2: Assess After 4 or More Attempts

Do not adjust the dose after a single use. The AUA and the European Association of Urology (EAU) both recommend a minimum of 4 to 6 attempts before declaring non-response [3][6]. Anxiety, unfamiliarity, and suboptimal timing can confound early results.

Step 3: Titrate Down or Up

If 10 mg produces adequate erections but side effects are bothersome (headache in ~15% of patients, dyspepsia in ~10% at this dose [2]), reduce to 5 mg. If 10 mg is well tolerated but erectile response is incomplete, increase to 20 mg. This ceiling applies to all on-demand patients, including those without interacting medications.

Dose-Response Data from Key Trials

In Brock et al.'s registration trial, the mean change from baseline in IIEF erectile function domain score was +6.5 with tadalafil 10 mg and +7.9 with tadalafil 20 mg, compared with +1.4 for placebo (P<0.001 for both) [2]. The 20 mg group reported a 75% successful intercourse rate by Sexual Encounter Profile question 3, versus 69% for 10 mg and 32% for placebo. The absolute difference between 10 and 20 mg was modest, which is why the label starts at 10, not 20.

Titration in Special Populations

Dose adjustments are mandatory in several clinical scenarios. A standard titration schedule assumes normal hepatic and renal function and no interacting medications, but many patients do not fit that profile.

Renal Impairment

For creatinine clearance 31 to 50 mL/min, the on-demand starting dose is 5 mg, with a maximum of 10 mg no more than once every 48 hours. For creatinine clearance <30 mL/min (including hemodialysis patients), the on-demand maximum is 5 mg. Daily dosing in severe renal impairment has not been extensively studied, and the FDA label advises caution [1]. A pharmacokinetic study by Forgue et al. showed a 40% increase in tadalafil AUC in men with creatinine clearance <30 mL/min [7].

Hepatic Impairment

Mild to moderate hepatic impairment (Child-Pugh A or B): the on-demand dose should not exceed 10 mg. Severe hepatic impairment (Child-Pugh C): tadalafil use is not recommended due to lack of safety data [1].

Older Adults

Age alone does not require dose reduction. However, older patients are more likely to be on alpha-blockers for BPH (tamsulosin, doxazosin) or antihypertensives. A pooled safety analysis found that men over 65 had similar adverse event rates to younger men at equivalent doses, but a greater incidence of postural dizziness when combining tadalafil with antihypertensives [5].

CYP3A4 Interaction Adjustments

Potent CYP3A4 inhibitors (ketoconazole 400 mg daily, ritonavir, clarithromycin): on-demand maximum is 10 mg every 72 hours. Daily maximum is 2.5 mg [1]. CYP3A4 inducers (rifampin, phenytoin, carbamazepine) may reduce tadalafil exposure, potentially requiring higher doses. No formal dose ceiling increase is recommended, but clinicians should anticipate reduced efficacy.

Monitoring During Titration

Titration without monitoring is guesswork. A structured follow-up protocol helps distinguish non-response from undertreated disease and catches early safety signals.

Baseline Assessments

Before initiating tadalafil, the clinician should document a cardiovascular risk assessment (the Princeton III Consensus classifies patients as low, intermediate, or high cardiac risk for sexual activity [8]), current medication list (especially nitrates, which are an absolute contraindication), and baseline SHIM/IIEF score. Measure blood pressure. Order fasting lipids and HbA1c if not recently checked, since metabolic disease commonly underlies ED.

Follow-Up at Each Titration Step

At each dose change, reassess the SHIM score, ask about the four most common adverse effects (headache, flushing, dyspepsia, back/limb pain), and recheck blood pressure if the patient is on antihypertensives or alpha-blockers. A drop in systolic blood pressure of more than 10 mmHg from baseline warrants holding the current dose or reducing it.

Red Flags That Halt Titration

Priapism (erection lasting more than 4 hours) requires emergency treatment and discontinuation. Sudden hearing loss or vision changes (anterior ischemic optic neuropathy, reported at a rate of <1 in 1,000 in post-marketing surveillance [1]) warrant immediate drug cessation and specialist referral. These events are rare. In over 15,000 patient-years of tadalafil exposure in clinical trials, the incidence of non-arteritic anterior ischemic optic neuropathy (NAION) did not exceed background rates in the general male population over 50 [1].

Switching Between Daily and On-Demand Regimens

Patients sometimes begin with one regimen and want to switch. This is clinically straightforward because the drug and its pharmacology do not change.

Daily to On-Demand

Stop the daily 2.5 or 5 mg tablet. Wait approximately 5 half-lives (roughly 4 days) for near-complete washout, then initiate on-demand dosing at 10 mg. Some clinicians skip the washout and simply instruct the patient to take 10 mg as needed starting the day after the last daily dose. Because the daily dose is low (2.5 to 5 mg) and the on-demand dose is higher, additive drug exposure during the overlap is unlikely to cause harm in patients without hepatic or renal impairment.

On-Demand to Daily

Begin the daily 2.5 mg tablet and discontinue on-demand use. Remind the patient that steady-state takes about 5 days, and that the first few sexual encounters during the transition may be less reliable. Do not combine a daily tablet with an additional on-demand dose.

Common Titration Mistakes

Several patterns lead to premature labeling of tadalafil as "not working."

Giving Up Too Early

The most frequent error is abandoning the drug after one or two unsuccessful attempts. The EAU's 2022 guidelines explicitly state that PDE5 inhibitor therapy should not be considered failed until the patient has made at least 4 to 6 attempts at the maximum tolerated dose [6]. Psychological factors, performance anxiety, and insufficient sexual stimulation can all mask drug efficacy.

Skipping the 10 mg Step

Some prescribers jump directly to 20 mg on-demand. While 20 mg is safe in most patients, starting there sacrifices the ability to titrate up. If 20 mg is partially effective, there is nowhere to go within the approved dose range. Starting at 10 mg preserves one step of upward adjustment.

Ignoring Drug Interactions

A patient on tamsulosin 0.4 mg who also starts tadalafil 20 mg on-demand without blood-pressure monitoring risks symptomatic hypotension. The FDA label recommends that patients on alpha-blockers be on a stable dose before adding tadalafil, and that tadalafil be started at the lowest recommended dose [1].

When Titration Fails: Next Steps

If a patient reaches 5 mg daily or 20 mg on-demand with an adequate trial (at least 4 to 6 attempts, proper timing, sexual stimulation present) and the SHIM score remains below 17, the prescriber should investigate further.

Reassess Underlying Conditions

Check testosterone (total and free), HbA1c, and lipid panel. In the Massachusetts Male Aging Study, diabetes tripled the probability of complete ED, and each 1 mmol/L increase in total cholesterol increased ED risk by 1.32-fold [9]. Treating the metabolic driver can restore PDE5 inhibitor responsiveness.

Consider Combination or Alternative Therapy

Adding a vacuum erection device for venous leak, switching to intracavernosal alprostadil for severe vasculogenic ED, or trialing a different PDE5 inhibitor (sildenafil, vardenafil, or avanafil) are all evidence-based options. The AUA guideline on ED recommends shared decision-making about next-line therapies when first-line oral agents fail [3].

Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and lead author of the AUA ED guideline, has stated: "PDE5 inhibitor non-response should prompt a full re-evaluation of the patient's vascular, hormonal, and psychological status before concluding that oral therapy has failed" [3].

The Endocrine Society's 2018 guideline adds: "In men with hypogonadism and ED, testosterone replacement should be initiated before or concurrently with PDE5 inhibitor therapy, as normalization of serum testosterone may restore drug responsiveness" [4].

Tadalafil Titration for BPH Without ED

Tadalafil 5 mg daily is the only PDE5 inhibitor approved for BPH/LUTS. There is no titration from 2.5 mg for this indication. The LVHP study (N=1,058) demonstrated that tadalafil 5 mg daily improved International Prostate Symptom Score (IPSS) by 4.7 points versus 2.3 for placebo at 12 weeks (P<0.001) [10]. The 2.5 mg dose did not reach statistical significance for IPSS improvement, which is why the BPH label specifies 5 mg.

Patients taking tadalafil 5 mg daily for BPH who also have ED are treated at the same dose. No additional on-demand dose should be added.